KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Research & Development: 2009-2024

Historic Research & Development for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $391.2 million.

  • Novavax's Research & Development rose 12.75% to $98.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.8 million, marking a year-over-year decrease of 17.87%. This contributed to the annual value of $391.2 million for FY2024, which is 46.96% down from last year.
  • As of FY2024, Novavax's Research & Development stood at $391.2 million, which was down 46.96% from $737.5 million recorded in FY2023.
  • Over the past 5 years, Novavax's Research & Development peaked at $2.5 billion during FY2021, and registered a low of $391.2 million during FY2024.
  • For the 3-year period, Novavax's Research & Development averaged around $788.0 million, with its median value being $737.5 million (2023).
  • As far as peak fluctuations go, Novavax's Research & Development surged by 556.20% in 2020, and later tumbled by 51.26% in 2022.
  • Yearly analysis of 5 years shows Novavax's Research & Development stood at $747.0 million in 2020, then soared by 239.28% to $2.5 billion in 2021, then slumped by 51.26% to $1.2 billion in 2022, then tumbled by 40.30% to $737.5 million in 2023, then plummeted by 46.96% to $391.2 million in 2024.